Tong Ren Tang Healthcare makes trading debut, backed by 39% annual patient growth - FT中文网
登录×
电子邮件/用户名
密码
记住我
请输入邮箱和密码进行绑定操作:
请输入手机号码,通过短信验证(目前仅支持中国大陆地区的手机号):
请您阅读我们的用户注册协议隐私权保护政策,点击下方按钮即视为您接受。
咏竹坊

Tong Ren Tang Healthcare makes trading debut, backed by 39% annual patient growth

The company will use a majority of the $68 million it raised from its Hong Kong listing to expand its network of traditional Chinese medicine hospitals and clinics
00:00

{"text":[[{"start":8.55,"text":"This article only represents the author's own views."}],[{"start":12.55,"text":"Is there still room for anything other than AI concept stocks in Hong Kong’s hottest IPO market in years, including companies that have made astronomical debuts despite short track records, little revenue and massive losses?"}],[{"start":27.450000000000003,"text":"Beijing Tong Ren Tang Healthcare Investment Co. Ltd. (2667.HK) is finding out with its trading debut on July 7 – its second attempt after a last-minute postponement of its original plan to debut in March amid market uncertainty."}],[{"start":43.900000000000006,"text":"The revised offering raised HK$532 million ($68 million), after the company calibrated a more conservative pricing strategy compared with its initial plans, signaling a more pragmatic valuation approach in the current market. It sold 108 million shares for HK$5.50 apiece."}],[{"start":65.25,"text":"50% cornerstone commitment"}],[{"start":67.85,"text":"Tong Ren Tang Healthcare secured cornerstone backing from Airport Port Technology Capital, Aurora SF and CICCFT, which together bought HK$296.1 million of the IPO shares, representing about 50% of the total on offer if the over-allotment option is not exercised. That underscores investor confidence in its traditional Chinese medicine (TCM) healthcare services business."}],[{"start":93,"text":"To cushion the share price around the listing, Tong Ren Tang Healthcare has deployed a team of stabilization dealers who can buy in the market if the price falls below the offer level in early trading. The mix of adjusted pricing, strong cornerstone backing and post-listing support are expected to deliver a smoother debut and protect investor value in a cautious Hong Kong IPO environment."}],[{"start":116.05,"text":"The firm now ranks as China’s largest private traditional Chinese medicine operator by patient visits, with annual visits growing 39.4% each year on average as it expands its network of hospitals, outpatient centers and clinics."}],[{"start":131.45,"text":"It operates 13 self-owned hospitals, outpatient healthcare centers and clinics, provides management services for another 13, and runs an internet hospital that pools TCM experts from across the country. It also cooperates with more than 500 external pharmacies, enabling it to send electronic prescriptions to partner pharmacies near customers."}],[{"start":154.04999999999998,"text":"A 357-year TCM brand"}],[{"start":157.35,"text":"Tong Ren Tang Healthcare has a 357-year pedigree to pitch to investors, as arguably the world’s oldest TCM brand. It’s worth noting the company’s promotion expenses were just 0.2% of revenue in 2025, a figure it links to the Tong Ren Tang brand moat and synergies across its integrated TCM business, spanning herbal sourcing, manufacturing, clinics and retail, which drives patient traffic and sales without heavy advertising."}],[{"start":185.45,"text":"Demographic aging and consumption upgrades are fueling strong demand for TCM, driven by rising needs for chronic disease management and preventive care, alongside broader adoption across age groups. At the same time, supportive policies under China’s 14th Five-Year Plan and expanded insurance coverage are providing long-term tailwinds, and a fragmented market with private institutions holding 54.9% share offers consolidation opportunities for leading players like Tong Ren Tang Healthcare."}],[{"start":216.45,"text":"According to research in the prospectus, the highly fragmented TCM market is expected to grow 9.5% annually between 2025 and 2030 to reach 1.7 trillion yuan ($251 million) by the end of that period. That offers Tong Ren Tang Healthcare the opportunity to act as a consolidator of the many local providers that operate at a small scale. The company plans to keep adding self-owned and managed facilities, while leveraging its online hospital and supply chain to standardize services and capture share from smaller competitors."}],[{"start":249.7,"text":"Reflecting its potential to emerge as a consolidator, three of the company’s self-owned facilities were acquired since 2022, including two in 2024. All three are in the affluent Yangtze River Delta region, including two in Shanghai, indicating the company intends to focus on regions with the greatest consumption power where it can fully leverage its well-known brand."}],[{"start":274.7,"text":"Tong Ren Tang Healthcare’s financials look respectable with its revenue remaining stable last year at 1.17 billion yuan, almost unchanged from 1.18 billion yuan the previous year."}],[{"start":286.7,"text":"Healthcare services, delivered by more than 2,700 physicians across its network, accounted for about 85% of revenue, rising slightly to 995 million yuan last year from 988 million yuan in 2024. Product sales, the second-largest category at around 13% of revenue, fell to 150 million yuan from 167 million yuan, as the company adjusted one of its recently acquired facilities to avoid competing with Tong Ren Tang Group."}],[{"start":316.7,"text":"Management services, while still small at 16.1 million yuan in revenue last year, show significant potential, as many independent TCM hospitals and clinics seek specialist operators to raise standards and quality. In a recent example, Tong Ren Tang Healthcare signed a collaboration agreement in April with Guizhou Maotai Hospital, partnering with another prominent name in the region known for China’s best-known liquor, Moutai."}],[{"start":343.9,"text":"The company reported a gross margin of 18.9% last year and its profit fell to 33.8 million yuan from 46.2 million yuan in 2024. It cautioned that the 2024 figure included a 17.1-million-yuan one-time gain from an asset sale that did not recur in 2025."}],[{"start":365.09999999999997,"text":"In its IPO prospectus, the company said it expects to use about 64% of its listing proceeds to expand its network and enhance its service capacity, including plans to acquire three to five medical institutions by the end of 2030. It also plans to open three medical institutions on its own or through joint ventures with partners using an asset-light model."}],[{"start":386.04999999999995,"text":"The less aggressive listing valuation looks likely to help Tong Ren Tang Healthcare cross the finish line this time, though it still faces the challenge of standing out in a crowded field. A sizable 16 firms made their trading debuts in the last week of June alone, and another 15, including Tong Ren Tang Healthcare, are set to start trading this week."}],[{"start":415.69999999999993,"text":""}]],"url":"https://audio.ftcn.net.cn/album/a_1783569916_9668.mp3"}

版权声明:本文版权归FT中文网所有,未经允许任何单位或个人不得转载,复制或以任何其他方式使用本文全部或部分,侵权必究。

加拿大企业担心特朗普关税引发“下行压力漩涡”

美加贸易战再起,与美国有业务往来的加拿大企业承受痛苦并面临不确定性。
27分钟前

FT社评:美财政部干预债券市场只是权宜之计

贝森特在日元和长期债券方面的举措,只能暂时缓解问题,无法解决政策可信度不足和债务过高的问题。

Lex专栏:希音首次公开募股推介应更多借鉴Meta而非H&M

它的竞争对手不只是服装零售商,还应包括任何为沉迷屏幕的用户带来多巴胺刺激的企业。

气候如何推动新的地缘战略?

环境变化正在重塑贸易、商业、物流和地缘政治。

“全民分担”的金融危机仍是危机

私募信贷与保险业的联姻热潮可能暗藏代价。

一周展望:美国通胀对债市的扰动有多大?

由于对美国40万亿美元的国家债务以及大量AI债券发行感到担忧,美国30年期借款利率已升至2007年以来的最高水平。
设置字号×
最小
较小
默认
较大
最大
分享×